DoJ Aims To ‘Do Something About’ Crime In FDA-Regulated Industries
This article was originally published in The Rose Sheet
In a frank warning at a recent FDLI conference, DoJ Director of Consumer Protection Michael Blume says the agency’s role is clear once it takes on a case investigated by FDA or FTC. “We are committed to prosecuting individuals, and we’re seeing that now, more and more,” Blume said.
You may also be interested in...
Claims promoting Cell Vitals’ ReLuma skin-care line render the products unapproved drugs, FDA asserts in a Nov. 24 warning letter. Marketed as “A Revolution in Stem Cell Skin Care,” the firm’s products feature cytokines and growth factors harvested from adult stem cells that send “grow and divide” signals to aging skin cells, the company says.
The Obama administration supports pressing criminal charges in cases of contaminated or adulterated supplements or food products, and the Department of Justice is “working closely” with FDA’s food safety center, says DoJ Consumer Protection Branch official Jeffrey Steger.
FDA will wield tight oversight of Johnson & Johnson subsidiary McNeil Consumer Healthcare's OTC manufacturing operations under a consent decree filed after the firm's quality-control changes failed to satisfy the agency.